THE LANCET
HIV

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Mills AM, Rizzardini G, Ramgopal MN, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. *Lancet HIV* 2024; published online May 8. https://doi.org/10.1016/S2352-3018(24)00030-4.

Table of Contents

Compliance (Medication Adherence)

In this study, the number of tablets remaining in study packaging was counted and reviewed at regular intervals. These results were used to calculate participant compliance.

For the main analysis of compliance, a day within the study was considered an “On-Therapy” day if the participant took at least 1 tablet from any bottle of study drug provided for this study.

The “Number of Days Should be On-Therapy” is the total number of days from Day 1 to the date of the last dose of study intervention for each participant. As such, the “Number of Days Should be On-Therapy” is the number of days from Day 1 to the date of the scheduled week 48 visit for those participants who are on study intervention for the entire study period. For participants who discontinue study intervention early (i.e., prior to completion of the study at week 48), the “Number of Days Should be On-Therapy” is the number of days from Day 1 to the date of discontinuation of study intervention.

For each participant, percent compliance was calculated using the following formula:

$$Percent\ Compliance = \frac{Number\ of\ Days\ on\ Therapy}{Number\ of\ Days\ Should\ be\ on\ Therapy}\ x\ 100$$

Table S1. Percentage of participants with HIV-1 RNA <50 copies/mL at week 48 by prognostic and demographic factors

Subgroup	Doravirine/islatravir (100/0·75 mg)		Bictegravir/emtricitabine/ tenofovir alafenamide		Difference, % (95% CI)[b]
	n/N	% (95% CI)[a]	n/N	% (95% CI)[a]	
Total	302/322	93·8 (90·6, 96·2)	301/319	94·4 (91·2, 96·6)	-0·6 (-4·4, 3·2)
Age (years)					
18 to 49	160/173	92·5 (87·5, 95·9)	163/175	93·1 (88·3, 96·4)	-0·7 (-6·4, 5·0)
50 to 64	115/121	95·0 (89·5, 98·2)	115/120	95·8 (90·5, 98·6)	-0·8 (-6·8, 5·1)
≥ 65	27/28	96·4 (81·7, 99·9)	23/24	95·8 (78·9, 99·9)	0·6 (-14·4, 17·4)
Sex					
Male	200/217	92·2 (87·8, 95·4)	232/242	95·9 (92·5, 98·0)	-3·7 (-8·5, 0·6)
Female	102/105	97·1 (91·9, 99·4)	69/77	89·6 (80·6, 95·4)	7·5 (0·5, 16·7)
Race					
White	227/240	94·6 (90·9, 97·1)	228/239	95·4 (91·9, 97·7)	-0·8 (-5·0, 3·3)
Black or African American	53/58	91·4 (81·0, 97·1)	50/55	90·9 (80·0, 97·0)	0·5 (-11·0, 12·3)
Asian	13/14	92·9 (66·1, 99·8)	12/13	92·3 (64·0, 99·8)	0·5 (-25·9, 28·2)
Other	9/10	90·0 (55·5, 99·7)	9/9	100·0 (66·4, 100·0)	-
Unknown	0/0	-	2/3	66·7 (9·4, 99·2)	-
Ethnicity					
Hispanic or Latino	59/64	92·2 (82·7, 97·4)	51/55	92·7 (82·4, 98·0)	-0·5 (-11·0, 10·5)
Not Hispanic or Latino	242/256	94·5 (91·0, 97·0)	246/259	95·0 (91·6, 97·3)	-0·4 (-4·5, 3·6)
Unknown	1/2	50·0 (1·3, 98·7)	4/5	80·0 (28·4, 99·5)	-
Duration of bictegravir/emtricitabine/tenofovir alafenamide prior to enrolment					
≥ 1 year	205/219	93·6 (89·5, 96·5)	209/218	95·9 (92·3, 98·1)	-2·3 (-6·8, 2·1)
< 1 year	97/103	94·2 (87·8, 97·8)	92/101	91·1 (83·8, 95·8)	3·1 (-4·5, 11·0)

[a]The within group CIs were calculated using the binomial Clopper-Pearson exact method.

[b]The CIs for the between group differences in percent response were calculated using the unstratified Miettinen and Nurminen method.

The treatment difference 95% CIs were calculated if there were at least 10 participants in each treatment group for each subgroup.

Table S2. Adverse events at week 48

	Doravirine/islatravir (100/0·75 mg) (n=322)	Bictegravir/emtricitabine/ tenofovir alafenamide (n=319)	Difference, % (95% CI)[a]
Blood and lymphatic system disorders	*3 (0.9)*	*4 (1.3)*	*-0.3 (-2.4, 1.6)*
Cardiac disorders	*9 (2.8)*	*8 (2.5)*	*0.3 (-2.4, 3.0)*
Ear and labyrinth disorders	*8 (2.5)*	*8 (2.5)*	*-0.0 (-2.7, 2.6)*
Vertigo	4 (1.2)	3 (0.9)	0.3 (-1.6, 2.3)
Eye disorders	*8 (2.5)*	*3 (0.9)*	*1.5 (-0.6, 4.0)*
Gastrointestinal disorders	*58 (18.0)*	*71 (22.3)*	*-4.2 (-10.5, 2.0)*
Abdominal discomfort	4 (1.2)	0 (0.0)	1.2 (0.0, 3.2)
Abdominal distension	1 (0.3)	6 (1.9)	-1.6 (-3.8, 0.1)
Abdominal pain	4 (1.2)	13 (4.1)	-2.8 (-5.8, -0.4)
Abdominal pain upper	4 (1.2)	3 (0.9)	0.3 (-1.6, 2.3)
Diarrhoea	8 (2.5)	20 (6.3)	-3.8 (-7.3, -0.7)
Dyspepsia	3 (0.9)	5 (1.6)	-0.6 (-2.8, 1.3)
Flatulence	3 (0.9)	5 (1.6)	-0.6 (-2.8, 1.3)
Gastrooesophageal reflux disease	3 (0.9)	7 (2.2)	-1.3 (-3.6, 0.8)
Haemorrhoids	4 (1.2)	3 (0.9)	0.3 (-1.6, 2.3)
Nausea	14 (4.3)	12 (3.8)	0.6 (-2.6, 3.8)
Toothache	2 (0.6)	6 (1.9)	-1.3 (-3.5, 0.6)
General disorders and administration site conditions	*32 (9.9)*	*29 (9.1)*	*0.8 (-3.8, 5.5)*
Asthenia	3 (0.9)	7 (2.2)	-1.3 (-3.6, 0.8)
Fatigue	11 (3.4)	8 (2.5)	0.9 (-1.9, 3.8)
Influenza like illness	1 (0.3)	4 (1.3)	-0.9 (-2.9, 0.6)
Pyrexia	9 (2.8)	3 (0.9)	1.9 (-0.3, 4.4)
Hepatobiliary disorders	*2 (0.6)*	*4 (1.3)*	*-0.6 (-2.6, 1.1)*
Immune system disorders	*2 (0.6)*	*4 (1.3)*	*-0.6 (-2.6, 1.1)*
Infections and infestations	*101 (31.4)*	*98 (30.7)*	*0.6 (-6.5, 7.8)*
COVID-19	19 (5.9)	18 (5.6)	0.3 (-3.5, 4.0)
Gastroenteritis	7 (2.2)	4 (1.3)	0.9 (-1.3, 3.3)
Herpes zoster	1 (0.3)	4 (1.3)	-0.9 (-2.9, 0.6)
Nasopharyngitis	9 (2.8)	3 (0.9)	1.9 (-0.3, 4.4)
Proctitis gonococcal	4 (1.2)	6 (1.9)	-0.6 (-3.0, 1.5)
Sinusitis	7 (2.2)	3 (0.9)	1.2 (-0.8, 3.6)
Syphilis	7 (2.2)	7 (2.2)	-0.0 (-2.6, 2.5)
Upper respiratory tract infection	6 (1.9)	2 (0.6)	1.2 (-0.6, 3.5)
Urinary tract infection	9 (2.8)	5 (1.6)	1.2 (-1.2, 3.9)
Injury, poisoning and procedural complications	*22 (6.8)*	*29 (9.1)*	*-2.3 (-6.6, 2.0)*
Accidental overdose	8 (2.5)	12 (3.8)	-1.3 (-4.3, 1.5)
Investigations	*29 (9.0)*	*26 (8.2)*	*0.9 (-3.6, 5.3)*
Alanine aminotransferase increased	0 (0.0)	6 (1.9)	-1.9 (-4.0, -0.7)
Aspartate aminotransferase increased	1 (0.3)	4 (1.3)	-0.9 (-2.9, 0.6)
SARS-CoV-2 test positive	6 (1.9)	3 (0.9)	0.9 (-1.1, 3.2)
Weight increased	5 (1.6)	6 (1.9)	-0.3 (-2.7, 1.9)
Metabolism and nutrition disorders	*14 (4.3)*	*20 (6.3)*	*-1.9 (-5.6, 1.6)*
Type 2 diabetes mellitus	2 (0.6)	4 (1.3)	-0.6 (-2.6, 1.1)
Vitamin D deficiency	4 (1.2)	5 (1.6)	-0.3 (-2.5, 1.8)

	Doravirine/islatravir (100/0·75 mg) (n=322)	Bictegravir/emtricitabine/ tenofovir alafenamide (n=319)	Difference, % (95% CI)[a]
Musculoskeletal and connective tissue disorders	*64 (19.9)*	*71 (22.3)*	*-2.4 (-8.7, 4.0)*
Arthralgia	17 (5.3)	19 (6.0)	-0.7 (-4.4, 3.0)
Arthritis	5 (1.6)	2 (0.6)	0.9 (-0.9, 3.0)
Back pain	13 (4.0)	17 (5.3)	-1.3 (-4.8, 2.1)
Muscle spasms	5 (1.6)	2 (0.6)	0.9 (-0.9, 3.0)
Musculoskeletal chest pain	4 (1.2)	2 (0.6)	0.6 (-1.2, 2.6)
Myalgia	7 (2.2)	9 (2.8)	-0.6 (-3.4, 2.0)
Neck pain	5 (1.6)	6 (1.9)	-0.3 (-2.7, 1.9)
Osteopenia	4 (1.2)	5 (1.6)	-0.3 (-2.5, 1.8)
Pain in extremity	3 (0.9)	5 (1.6)	-0.6 (-2.8, 1.3)
Tendonitis	1 (0.3)	5 (1.6)	-1.3 (-3.3, 0.3)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	*6 (1.9)*	*9 (2.8)*	*-1.0 (-3.6, 1.5)*
Nervous system disorders	*46 (14.3)*	*51 (16.0)*	*-1.7 (-7.3, 3.9)*
Dizziness	6 (1.9)	9 (2.8)	-1.0 (-3.6, 1.5)
Headache	25 (7.8)	23 (7.2)	0.6 (-3.6, 4.8)
Hypoaesthesia	1 (0.3)	4 (1.3)	-0.9 (-2.9, 0.6)
Neuropathy peripheral	4 (1.2)	0 (0.0)	1.2 (0.0, 3.2)
Paraesthesia	6 (1.9)	3 (0.9)	0.9 (-1.1, 3.2)
Sciatica	4 (1.2)	3 (0.9)	0.3 (-1.6, 2.3)
Psychiatric disorders	*34 (10.6)*	*37 (11.6)*	*-1.0 (-6.0, 3.9)*
Abnormal dreams	1 (0.3)	5 (1.6)	-1.3 (-3.3, 0.3)
Anxiety	8 (2.5)	10 (3.1)	-0.7 (-3.5, 2.1)
Depression	8 (2.5)	5 (1.6)	0.9 (-1.4, 3.5)
Insomnia	15 (4.7)	7 (2.2)	2.5 (-0.4, 5.6)
Renal and urinary disorders	*7 (2.2)*	*11 (3.4)*	*-1.3 (-4.2, 1.4)*
Reproductive system and breast disorders	*16 (5.0)*	*9 (2.8)*	*2.1 (-0.9, 5.4)*
Erectile dysfunction	4 (1.2)	2 (0.6)	0.6 (-1.2, 2.6)
Respiratory, thoracic and mediastinal disorders	*19 (5.9)*	*30 (9.4)*	*-3.5 (-7.8, 0.6)*
Asthma	4 (1.2)	4 (1.3)	-0.0 (-2.1, 2.0)
Cough	7 (2.2)	11 (3.4)	-1.3 (-4.2, 1.4)
Oropharyngeal pain	0 (0.0)	5 (1.6)	-1.6 (-3.6, -0.4)
Rhinitis allergic	2 (0.6)	5 (1.6)	-0.9 (-3.1, 0.9)
Skin and subcutaneous tissue disorders	*33 (10.2)*	*39 (12.2)*	*-2.0 (-7.0, 3.0)*
Eczema	2 (0.6)	4 (1.3)	-0.6 (-2.6, 1.1)
Pruritus	5 (1.6)	5 (1.6)	-0.0 (-2.3, 2.2)
Rash	4 (1.2)	6 (1.9)	-0.6 (-3.0, 1.5)
Vascular disorders	*7 (2.2)*	*18 (5.6)*	*-3.5 (-6.8, -0.5)*
Hypertension	4 (1.2)	14 (4.4)	-3.1 (-6.1, -0.7)

[a]Based on Miettinen & Nurminen method.

Data are n (%).

For an adverse event to be included in this table, it had to occur in at least 4 participants in at least one of the treatment groups. This pre-specified incidence cutoff was chosen because with the given sample size, 95% confidence intervals for adverse events occurring in fewer than 4 participants are unlikely to be able to show between group differences.

Table S3. Infections at week 48

	Doravirine/islatravir (100/0·75 mg) (n=322)	Bictegravir/emtricitabine/ tenofovir alafenamide (n=319)
Abscess limb	1 (0·3)	0 (0·0)
Acarodermatitis	1 (0·3)	0 (0·0)
Acute sinusitis	3 (0·9)	1 (0·3)
Anal chlamydia infection	1 (0·3)	3 (0·9)
Atypical pneumonia	1 (0·3)	0 (0·0)
Bacterial vaginosis	0 (0·0)	1 (0·3)
Blastocystis infection	0 (0·0)	1 (0·3)
Body tinea	1 (0·3)	2 (0·6)
Breast abscess	1 (0·3)	0 (0·0)
Bronchitis	1 (0·3)	1 (0·3)
COVID-19	19 (5·9)	18 (5·6)
COVID-19 pneumonia	1 (0·3)	0 (0·0)
Cellulitis	3 (0·9)	2 (0·6)
Chlamydial infection	3 (0·9)	3 (0·9)
Clostridium difficile colitis	1 (0·3)	0 (0·0)
Coccidioidomycosis	0 (0·0)	1 (0·3)
Conjunctivitis	2 (0·6)	2 (0·6)
Conjunctivitis bacterial	0 (0·0)	1 (0·3)
Cystitis	1 (0·3)	2 (0·6)
Cystitis escherichia	1 (0·3)	0 (0·0)
Device related infection	0 (0·0)	1 (0·3)
Ear infection	2 (0·6)	0 (0·0)
Endocarditis bacterial	0 (0·0)	1 (0·3)
Escherichia urinary tract infection	0 (0·0)	1 (0·3)
Folliculitis	1 (0·3)	2 (0·6)
Fungal skin infection	1 (0·3)	1 (0·3)
Furuncle	0 (0·0)	2 (0·6)
Gastroenteritis	7 (2·2)	4 (1·3)
Gastroenteritis viral	2 (0·6)	0 (0·0)
Genital herpes	0 (0·0)	2 (0·6)
Genital infection	0 (0·0)	1 (0·3)
Genital infection fungal	0 (0·0)	1 (0·3)
Genitourinary chlamydia infection	0 (0·0)	1 (0·3)
Genitourinary tract gonococcal infection	0 (0·0)	2 (0·6)
Giardiasis	0 (0·0)	1 (0·3)
Gingivitis	3 (0·9)	1 (0·3)
Gonorrhoea	3 (0·9)	3 (0·9)
Helicobacter gastritis	0 (0·0)	1 (0·3)
Hepatitis B	1 (0·3)	0 (0·0)
Hepatitis B reactivation	1 (0·3)	0 (0·0)
Herpes simplex	1 (0·3)	0 (0·0)
Herpes virus infection	0 (0·0)	1 (0·3)
Herpes zoster	1 (0·3)	4 (1·3)
Hordeolum	0 (0·0)	2 (0·6)
Impetigo	0 (0·0)	1 (0·3)
Infected dermal cyst	0 (0·0)	1 (0·3)
Infection	1 (0·3)	1 (0·3)
Influenza	1 (0·3)	3 (0·9)
Joint abscess	1 (0·3)	0 (0·0)
Latent syphilis	1 (0·3)	0 (0·0)
Lower respiratory tract infection	2 (0·6)	0 (0·0)
Mastitis bacterial	1 (0·3)	0 (0·0)

	Doravirine/islatravir (100/0·75 mg) (n=322)	Bictegravir/emtricitabine/ tenofovir alafenamide (n=319)
Nasopharyngitis	9 (2·8)	3 (0·9)
Neurosyphilis	1 (0·3)	0 (0·0)
Nipple infection	0 (0·0)	1 (0·3)
Oesophageal candidiasis	1 (0·3)	0 (0·0)
Onychomycosis	1 (0·3)	0 (0·0)
Oral herpes	3 (0·9)	3 (0·9)
Orchitis	0 (0·0)	1 (0·3)
Oropharyngeal gonococcal infection	2 (0·6)	2 (0·6)
Otitis externa	0 (0·0)	2 (0·6)
Otitis media	0 (0·0)	2 (0·6)
Paronychia	1 (0·3)	0 (0·0)
Pharyngitis	1 (0·3)	2 (0·6)
Pilonidal cyst	1 (0·3)	0 (0·0)
Pneumonia	0 (0·0)	2 (0·6)
Proctitis chlamydial	2 (0·6)	2 (0·6)
Proctitis gonococcal	4 (1·2)	6 (1·9)
Proctitis mycoplasmal	1 (0·3)	1 (0·3)
Pyelonephritis	0 (0·0)	1 (0·3)
Respiratory tract infection	0 (0·0)	1 (0·3)
Rhinitis	0 (0·0)	1 (0·3)
Root canal infection	0 (0·0)	2 (0·6)
Secondary syphilis	0 (0·0)	1 (0·3)
Sepsis	0 (0·0)	1 (0·3)
Sinusitis	7 (2·2)	3 (0·9)
Skin candida	0 (0·0)	1 (0·3)
Subcutaneous abscess	1 (0·3)	0 (0·0)
Syphilis	7 (2·2)	7 (2·2)
Tinea versicolour	0 (0·0)	2 (0·6)
Tonsillitis	1 (0·3)	2 (0·6)
Tooth abscess	0 (0·0)	2 (0·6)
Tooth infection	0 (0·0)	1 (0·3)
Trichomoniasis	1 (0·3)	0 (0·0)
Trichophytosis	0 (0·0)	1 (0·3)
Upper respiratory tract infection	6 (1·9)	2 (0·6)
Urethritis	1 (0·3)	3 (0·9)
Urethritis chlamydial	0 (0·0)	1 (0·3)
Urethritis gonococcal	1 (0·3)	1 (0·3)
Urethritis mycoplasmal	0 (0·0)	1 (0·3)
Urinary tract candidiasis	0 (0·0)	1 (0·3)
Urinary tract infection	9 (2·8)	5 (1·6)
Vaginal infection	1 (0·3)	0 (0·0)
Vaginitis gardnerella	0 (0·0)	1 (0·3)
Viral infection	1 (0·3)	1 (0·3)
Viral upper respiratory tract infection	1 (0·3)	0 (0·0)
Vulvovaginal candidiasis	1 (0·3)	0 (0·0)
Vulvovaginal mycotic infection	1 (0·3)	0 (0·0)
Wound infection	2 (0·6)	0 (0·0)

Data are n (%).

Table S4. Adverse events by maximum toxicity grade

	Doravirine/islatravir (100/0·75 mg) (n=322)	Bictegravir/emtricitabine/ tenofovir alafenamide (n=319)
All adverse events	229 (71.1%)	238 (74.6%)
Grade 1	109 (33.9%)	102 (32.0%)
Grade 2	92 (28.6%)	109 (34.2%)
Grade 3	24 (7.5%)	24 (7.5%)
Grade 4	4 (1.2%)	3 (0.9%)
Treatment-related adverse events	32 (9.9%)	38 (11.9%)
Grade 1	22 (6.8%)	23 (7.2%)
Grade 2	8 (2.5%)	13 (4.1%)
Grade 3	2 (0.6%)	2 (0.6%)

Data are n (%).
Only the highest reported grade of a given adverse event is counted for the individual participant.
Grades are based on the NIH DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, July 2017, version 2·1.

Table S5. Grade 3 or 4 laboratory abnormalities in ≥4 participants

Test Name (Unit)	Criterion*	Doravirine/islatravir (100/0·75 mg)	Bictegravir/emtricitabine/ tenofovir alafenamide	Difference, % (95% CI)
Chemistry				
Creatinine kinase (IU/L)	Grade 3: 10·0 to <20·0 x ULN	4/322 (1.2%)	2/317 (0.6%)	0·6 (-1·2, 2·6)
Fasting glucose (mg/dL)	Grade 3: >250 to <500	3/308 (1.0%)	5/313 (1.6%)	-0·6 (-2·8, 1·4)
Lipase (IU/L)	Grade 3: 3·0 to <5·0 x ULN	5/322 (1.6%)	8/317 (2.5%)	-1·0 (-3·5, 1·4)
Non-fasting glucose (mg/dL)	Grade 3: >250 to <500	4/300 (1.3%)	4/300 (1.3%)	0·0 (-2·2, 2·2)
Fasting lipids				
LDL cholesterol (mg/dL)	Grade 3: ≥190	7/302 (2.3%)	7/304 (2.3%)	0·0 (-2·6, 2·7)
Renal parameters				
Creatinine (mg/dL)	Grade 3: >1·8 to <3·5 x ULN, or 1·5 to <2·0 x baseline	2/322 (0.6%)	6/317 (1.9%)	-1·3 (-3·5, 0·6)[+]
Creatinine clearance (mL/min)	Grade 3: <60 to 30, or 30% to <50% decrease from baseline	5/322 (1.6%)	15/317 (4.7%)	-3·2 (-6·3, -0·5)[+]
GFR from creatinine (mL/min/1·73m^2)	Grade 3: <60 to 30, or 30% to <50% decrease from baseline	4/321 (1.2%)	29/317 (9.1%)	-7·9 (-11·7, -4·7)[+]

Data are n/m (%), where m = number of participants with a baseline and at least one post-baseline test result.

*For graded criteria, participants are counted once per test in the highest grade reported· Only participants with a worsened grade from baseline were included.

[+]Higher incidence of Grade 3 changes in the bictegravir/emtricitabine/tenofovir alafenamide group is an artifact from the inhibitory effect of bictegravir on tubular secretion of creatinine.

GFR = glomerular filtration rate; LDL-C = low-density lipoprotein; ULN = Upper limit of normal range.

Table S6. Mean change and percent change from baseline in hip and spine bone mineral density (g/cm^2) to week 48

Site	Visit	n	Doravirine/islatravir (100/0·75 mg)	n	Bictegravir/emtricitabine/ tenofovir alafenamide	Difference, % (95% CI)[b]
Hip BMD, Mean (95% CI)[a]	Baseline	255	0.98	240	1.01	-
	Week 48 change from baseline	231	-0.0033 (-0.0065, -0.0001)	207	-0.0017 (-0.0046, 0.0011)	-0.0020 (-0.0064, 0.0023)
Spine BMD, Mean (95% CI)[a]	Baseline	256	1.10	241	1.14	-
	Week 48 change from baseline	232	-0.0038 (-0.0081, 0.0005)	209	0.0006 (-0.0039, 0.0051)	-0.0050 (-0.0113, 0.0012)
Hip BMD, % Mean Change (95% CI)[a]	Baseline	255	0.98	240	1.01	-
	Week 48 change from baseline	231	-0.3160 (-0.6640, 0.0320)	207	-0.1417 (-0.4247, 0.1412)	-0.2133 (-0.6689, 0.2423)
Spine BMD, % Mean Change (95% CI)[a]	Baseline	256	1.10	241	1.14	-
	Week 48 change from baseline	232	-0.3108 (-0.6962, 0.0747)	209	0.1021 (-0.2951, 0.4993)	-0.4669 (-1.0211, 0.0872)

[a]Within-group 95% CIs were based on the t-distribution.

[b]The 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.

Figure S1. Mean change in weight from baseline to week 48



B/F/TAF=bictegravir/emtricitabine/tenofovir alafenamide; DOR/ISL=doravirine/islatravir.

Figure S2. Mean change in LDL-C, non-HDL-C, and total cholesterol/HDL-C ratio from baseline to week 48



Excluding participants who took lipid-lowering therapy during the study.
B/F/TAF=bictegravir/emtricitabine/tenofovir alafenamide; DOR/ISL=doravirine/islatravir; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol.

MK-8591A-018 Primary Investigators By Country

Australia: Mark Bloch, Andrew Carr, Beng Hor Eu, Robert Finlayson, Kenneth Koh, Julian Langton-Lockton; *Austria*: Sylvia Hartl, Andreas Kapper, Armin Rieger, Alexander Zoufaly; *Canada*: Brian Conway, Fiona Smaill, Jason Szabo, Benoit Trottier; *Finland*: Jussi Sutinen; *France*: Faiza Ajana, Eric Cua, Laurent Hocqueloux, Christine Katlama, Karine Lacombe, Jean-Michel Livrozet, Patrick Philibert, Gilles Pialoux, Francois Raffi, Jacques Reynes, David Zucman *Germany*: Keikawus Arasteh, Markus Bickel, Johannes R· Bogner, Olaf Degen, Stefan Esser, Jukka Hartikainen, Celia Jonsson-Oldenbuettel, Jürgen K· Rockstroh, Christoph D· Spinner, Hans-Jürgen Stellbrink, Matthias Stoll; *Italy*: Antonella Castagna, Antonella D'Arminio Monforte, Andrea Gori, Giuliano Rizzardini; *Japan*: Shinichi Oka, Takuma Shirasaka, Yoshiyuki Yokomaku; *Spain*: Juan Berenguer, Vicenc Falco Ferer, Josep Mallolas Masferrer, Santiago Moreno Guillen, Roger Paredes, Ignacio Perez Valero, Daniel Podzamczer Palter, Rafael Rubio Garcia, Jesus Santos Gonzalez, Jesus Troya Garcia; *United States*: Christopher J· Bettacchi, Michelle Cespedes, Daniel R· Coulston, Gordon Crofoot, Douglas Cunningham, Craig Dietz, Robin Dretler, Debbie P· Hagins, William K· Henry, Federico Hinestrosa, Harold Katner, Anthony LaMarca, Anthony M· Mills, Javier Morales-Ramirez, Ronald G· Nahass, Cheryl Newman, Olayemi O· Osiyemi, Moti N· Ramgopal, Lizette Santiago, Anthony Scarsella, Anita Scribner, Peter Shalit, William Towner, Sarah Waldman